CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

CARGO Therapeutics

Today we announced the appointment of Michael Ports, PhD, as Chief Scientific Officer. In this role at CARGO, Dr. Ports will be responsible for advancing our proprietary platform technologies and discovery-stage programs. Learn more: https://bit.ly/45QfufU

Today at the 8th CAR-TCR Summit in Boston, John Rossi, CARGO’s Vice President and Head of Translational Medicine, is presenting on strategies to deliver next generation engineered CAR T-cell therapy products to overcome resistance. John is also participating in a roundtable discussion on mechanisms of resistance and how to overcome them. Learn more here: https://lnkd.in/dn-KZVN 
#CARTCR #celltherapy #CART

Today we announced the addition of independent directors to our Board of Directors, bringing together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in #CART therapies and #oncology. Learn more: https://bit.ly/47KuJIs

At CARGO, we are on a mission to advance next generation #CART therapies – and we are growing! We’re currently searching for a Medical Director to join our team. In this role, you’ll leverage your strong experience working across the clinical team to identify, influence and support priority initiatives while contributing to the leadership team and the advancement of CARGO cell therapy products. Review the job description here: https://lnkd.in/gRZYD2_3
#hiring #biotechjobs #celltherapy


Congratulations to our co-founder Crystal Mackall, MD, who was recently featured in an Endpoints News special report on 20 women reshaping biopharma for her pioneering work in the CAR T-cell therapy and oncology fields and her commitment to advocating for the next generation of women in biopharma! https://bit.ly/45qvyEz 
#CART #celltherapy #oncology

We are thrilled to participate in WuXi AppTec's BOLD: Innovation That Matters online series today! Our CEO Gina Simmons Chapman shares more about our work to advance #CART therapies for cancer during the spotlight session on the next wave of cancer therapeutics. Learn more and tune in here: https://bit.ly/43s85kM #TakingBOLDAction 

	Dec '21	Dec '22	Dec '23
account payables	818K -	3.48M 325.79%	5.01M 43.93%
accumulated other comprehensive income loss
cash and cash equivalents	41K -	1.87M 4,465.85%	405.73M 21,573.72%
cash and short term investments	41K -	1.87M 4,465.85%	405.73M 21,573.72%
common stock	11K -	15K 36.36%	41K 173.33%
deferred revenue	593K -	4.65M 684.82%	12.84M 175.89%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	2.23M -	1.09M 51.03%	26.26M 2,305.04%
long term investments
net debt	3.13M -	22.13M 607.77%	-377.19M 1,804.28%
net receivables		476K -	1.74M 265.34%
other assets
other current assets
other current liabilities	693K -	17.74M 2,460.17%	1.03M 94.19%
other liabilities
other non current assets	442K -	783K 77.15%	4.96M 533.21%
other non current liabilities		250K -	225K 10%
othertotal stockholders equity	5.86M -	11.74M 100.43%	550.49M 4,590.22%
preferred stock	6K -	11K 83.33%
property plant equipment net	3.88M -	5.53M 42.68%	38.60M 597.65%
retained earnings	-6.05M -	-47.00M 677.10%	-145.15M 208.83%
short term debt	938K -	22.91M 2,342.64%	2.28M 90.06%
short term investments
tax assets
tax payables
total assets	4.50M -	10.24M 127.42%	453.04M 4,322.88%
total current assets	184K -	3.93M 2,034.24%	409.48M 10,327.22%
total current liabilities	2.45M -	44.14M 1,702.25%	21.16M 52.05%
total debt	3.17M -	24.00M 657.70%	28.54M 18.90%
total investments
total liabilities	4.68M -	45.48M 871.98%	47.65M 4.77%
total liabilities and stockholders equity	4.50M -	10.24M 127.42%	453.04M 4,322.88%
total non current assets	4.32M -	6.32M 46.20%	43.56M 589.66%
total non current liabilities	2.23M -	1.34M 39.82%	26.49M 1,873.77%
total stockholders equity	-175K -	-35.24M 20,034.86%	405.39M 1,250.49%

CRGX

COM:CARGO-TX

CARGO Therapeutics

Last Close

15.73

22/11 21:00

Market Cap

761.31M

Beta: -

Volume Today

156.59K

Avg: -

Preview